Skip to main content

Generic Twyneo Availability

Last updated on Nov 8, 2022.

Twyneo is a brand name of benzoyl peroxide/tretinoin topical, approved by the FDA in the following formulation(s):

TWYNEO (benzoyl peroxide; tretinoin - cream;topical)

Has a generic version of Twyneo been approved?

No. There is currently no therapeutically equivalent version of Twyneo available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Twyneo. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Patent 10,420,743

    Patent expiration dates:

    • July 12, 2038
      ✓ 
      Patent use: TOPICAL TREATMENT OF ACNE VULGARIS IN ADULTS AND PEDIATRIC PATIENTS 9 YEARS OF AGE AND OLDER
  • Patent 10,653,899

    Patent expiration dates:

    • December 30, 2030
      ✓ 
      Patent use: TOPICAL TREATMENT OF ACNE VULGARIS IN ADULTS AND PEDIATRIC PATIENTS 9 YEARS OF AGE AND OLDER
      ✓ 
      Drug product
  • Patent 11,071,878

    Patent expiration dates:

    • December 30, 2030
      ✓ 
      Drug product
  • Compositions for topical application comprising a peroxide and retinoid
    Patent 8,617,580
    Issued: December 31, 2013
    Assignee(s): Sol-Gel Technologies Ltd.

    The invention relates to a composition for topical application comprising as an active ingredient a peroxide and a retinoid wherein one of said peroxide and retinoid is in the form of first microparticles comprising a solid particulate matter of the active ingredient coated by a metal oxide layer and the other of said peroxide and retinoid is present in an uncoated free form or in a coated form of the active ingredient. The invention further relates to method for treating a surface condition in a subject using said composition, a method for preparing a composition exhibiting improved stability, and a kit comprising: (a) a first composition comprising a peroxide as a first active ingredient; and (b) a second composition comprising a retinoid as a second active ingredient; at least one of said first and said second active ingredient being coated by a metal oxide layer.

    Patent expiration dates:

    • February 3, 2028
      ✓ 
      Drug product
  • Metal oxide coating of water insoluble ingredients
    Patent 9,868,103
    Issued: January 16, 2018
    Assignee(s): SOL-GEL TECHNOLOGIES LTD.

    The invention relates to process for coating a solid, water-insoluble particulate matter, with a metal oxide comprising: (a) contacting the solid water-insoluble particulate matter with a cationic additive in an aqueous medium to obtain a dispersion of said particulate matter having a positive zeta potential; (b) coating the solid water-insoluble particulate matter by precipitation of a metal oxide salt onto the surface of the particulate matter, forming a metal oxide layer thereon; and (c) aging said coating layer. The invention further relates to coated particulate matter obtained by the process and to compositions comprising solid, water-insoluble particulate matter, coated by a metal oxide layer, the particulate matter being a dermatological active agent or a pesticide. The invention additionally relates to methods of treating a surface condition in a subject using compositions comprising solid, water insoluble dermatologically active agent, coated by a metal oxide layer.

    Patent expiration dates:

    • August 8, 2028
      ✓ 
      Patent use: TOPICAL TREATMENT OF ACNE VULGARIS IN ADULTS AND PEDIATRIC PATIENTS 9 YEARS OF AGE AND OLDER
      ✓ 
      Drug product

Related exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:

    • July 26, 2024 - NEW COMBINATION

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.